Get the Stockscreener App
3.30
2.65%
-0.09
After Hours:
3.31
0.01
+0.30%
Cellectar Biosciences Inc stock is traded at $3.30, with a volume of 52,493.
It is down -2.65% in the last 24 hours and down -42.91% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$3.39
Open:
$3.43
24h Volume:
52,493
Relative Volume:
0.29
Market Cap:
$10.53M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.0154
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-8.08%
1M Performance:
-42.91%
6M Performance:
+1,119%
1Y Performance:
+62.56%
1-Day Range:
$3.20
$3.43
1-Week Range:
$3.20
$3.61
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.30 | 10.82M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Will Cellectar Biosciences Inc. bounce back from current supportJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Is Cellectar Biosciences Inc. stock a top pick in earnings seasonAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Will Cellectar Biosciences Inc. (NV4) stock deliver compounding returnsLong Setup & Risk Controlled Swing Alerts - newser.com
Can Cellectar Biosciences Inc. stock hit record highs again2025 Key Highlights & AI Enhanced Trading Signals - newser.com
How strong is Cellectar Biosciences Inc. (NV4) stock earnings growthJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Using R and stats models for Cellectar Biosciences Inc. forecastingPortfolio Update Report & Technical Confirmation Alerts - newser.com
Is now a turning point for Cellectar Biosciences Inc.2025 Market WrapUp & Safe Capital Growth Tips - newser.com
How analysts rate Cellectar Biosciences Inc. stock today2025 Retail Activity & Real-Time Volume Analysis - newser.com
What the charts say about Cellectar Biosciences Inc. today2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
Will Cellectar Biosciences Inc. stock pay special dividendsJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - newser.com
Can Cellectar Biosciences Inc. stock surprise with earnings upside2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
Will Cellectar Biosciences Inc. benefit from macro trendsTrade Risk Assessment & Low Drawdown Investment Ideas - newser.com
Published on: 2025-11-03 03:03:40 - newser.com
How hedge fund analytics apply to Cellectar Biosciences Inc. stock2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
Why Cellectar Biosciences Inc. stock could outperform in 2025July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - newser.com
Using RSI to spot recovery in Cellectar Biosciences Inc.Chart Signals & Weekly High Return Stock Opportunities - newser.com
Will Cellectar Biosciences Inc. stock gain from government policies2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Can Cellectar Biosciences Inc. stock deliver sustainable ROEJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Using data tools to time your Cellectar Biosciences Inc. exitJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Using data filters to optimize entry into Cellectar Biosciences Inc.Market Performance Report & AI Powered Market Entry Strategies - newser.com
Is Cellectar Biosciences Inc. stock a safe investment in uncertain markets2025 Price Action Summary & Free Technical Pattern Based Buy Signals - newser.com
Is Cellectar Biosciences Inc. stock a buy in volatile marketsJuly 2025 Spike Watch & Long-Term Safe Return Strategies - newser.com
How Cellectar Biosciences Inc. (NV4) stock correlates with oil marketsWeekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Morguard Real Estate Investment Trust T0L a good long term investmentBlue Chip Stock Analysis & Free Long-Term Investment Planning - earlytimes.in
Cellectar Biosciences Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Small Capital Growth Tips - earlytimes.in
Can Cellectar Biosciences Inc. hit a new high this month2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Why analysts remain bullish on Cellectar Biosciences Inc. stock2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Can Cellectar Biosciences Inc. stock weather global recessionGap Up & Fast Entry Momentum Trade Alerts - newser.com
Has Cellectar Biosciences Inc. found a price floor2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Cellectar Biosciences Inc. strategiesQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Cellectar Biosciences, Inc. (CLRB) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Published on: 2025-11-01 12:28:59 - newser.com
Published on: 2025-11-01 05:42:39 - newser.com
Is Cellectar Biosciences Inc. (NV4) stock supported by strong fundamentalsAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
Published on: 2025-11-01 03:42:44 - newser.com
Will Cellectar Biosciences Inc. (NV4) stock split increase liquidity2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):